Zhejiang Orient Gene Biotech Co., Ltd. was registered and established.
Zhejiang Provincial Postdoctoral Research Station was established.
The Huzhou Academician Expert Workstation was established and recognized as a National High-tech Enterprise.
Passed the field inspection of US FDA with zero defects.
Hangzhou D&W was established to enter the field of molecular diagnosis.
The company accelerated the globalization and the business layout of the whole industrial chain, set up Healgen and Shanghai Douglas as the international sales platforms
Canada Healstone and Qingdao Handsen as the R&D platforms of antigens and antibodies
Nanjing Healvity as a diagnostic instrument platform
Hangzhou ShineDo as a liquid biochip platform
The company completed the joint-stock company restructuring. This year, the company has achieved an operating income of more than 200 million yuan, and at the same time, has established Hangzhou Wanzijian as a domestic sales platform.
The company’s malaria detection kit was selected and funded by the Bill & Melinda Gates Foundation for pre-certification by the World Health Organization.
The company cooperated with Shanghai Jiaotong University on liquid biochip related technologies; meanwhile, the company has been deeply involved in the international market, with customers in more than 120 countries and regions around the world.
The IPO stock of the company was listed on the STAR Market at Shanghai Stock Exchange
The company successfully developed the COVID-19 antibody/nucleic acid/antigen detection reagent, which helped the global epidemic situation
In the first half of the year, the company achieved an operating income of 828 million yuan, achieving a major breakthrough in the bottleneck of development scale.